A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2005
This Phase II study is being conducted in treatment-naive patients (no previous antiviral therapy for Hepatitis C infection) with genotype-1 chronic hepatitis C to evaluate the safety and effectiveness of valopicitabine alone and together with Pegylated Interferon (a drug approved by the Food and Drug Administration for the treatment of Hepatitis C infection).
Epistemonikos ID: ae60d9beb5b432a1c56137b8f317c6c8b00224e0
First added on: May 04, 2024